Chen, Shuming
McMiller, Tracee L.
Soni, Abha
Succaria, Farah
Sidhom, John-William
Cappelli, Laura C.
Casciola-Rosen, Livia A.
Morales, Isaac R.
Sankaran, Preethi
Berger, Alan E.
Deutsch, Julie Stein
Zhu, Qingfeng C.
Anders, Robert A.
Hooper, Jody E.
Pardoll, Drew M.
Lipson, Evan J.
Taube, Janis M.
Topalian, Suzanne L. http://orcid.org/0000-0002-0821-8587
Funding for this research was provided by:
Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
National Institutes of Cancer (R01 CA142779)
Melanoma Research Alliance
MaryJo & Brian C. Rogers Fund
Barney Family Foundation
Moving for Melanoma of Delaware
Laverna Hahn Charitable Trust
Donald B. and Dorothy L. Stabler Foundation
National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23AR075872)
National Institute of Cancer (P30CA006973)
Article History
Received: 22 January 2024
Accepted: 9 February 2024
First Online: 5 March 2024
Declarations
:
: This study was approved by the Johns Hopkins Medicine Institutional Review Board.
: Not applicable.
: LCC is a consultant for Amgen, Bristol Myers Squibb, and Mallinckrodt, and receives research funding from Bristol Myers Squibb. RAA receives research support from Bristol Myers Squibb and RAPT Therapeutics, and serves on advisory boards or consults for AstraZeneca, Bristol Myers Squibb, and Merck SD. EJL is an advisor/consultant for Bristol Myers Squibb, CareDX, Eisai, Genentech, HUYA Bioscience International, Immunocore, Instil Bio, Merck, Natera, Nektar, Novartis, Oncosec, Pfizer, Rain Therapeutics, Regeneron, Replimune, and Sanofi, and has research funding from Bristol Myers Squibb, Haystack Oncology, Merck, Regeneron, and Sanofi. DMP and SLT receive consulting fees from Amgen, Bristol Myers Squibb, Compugen, Dragonfly Therapeutics, Janssen Pharmaceuticals, Normunity, PathAI, RAPT Therapeutics, Regeneron, Takeda Pharmaceuticals, and Tizona LLC; receive research grants from Bristol Myers Squibb, Compugen, and Immunomic Therapeutics; have stock options or stock in Atengen Inc., DNAtrix, Dracen, Dragonfly Therapeutics, ManaT Bio, RAPT Therapeutics, and Tizona LLC; and have patents related to T-cell regulatory molecules including LAG-3, and the treatment of MSI-high cancers with anti-PD-1. JMT reports research grants and consulting fees from Akoya Biosciences and Bristol Myers Squibb; consulting for AstraZeneca, Compugen, Genentech, GlaxoSmithKline, Lunaphore, Merck, Regeneron and Roche; and an institutional patent filed on machine learning for scoring pathologic response to immunotherapy. TLM, AS, FS, J-WS, LAC-R, IRM, PS, AEB, JSD, QCZ, and JEH declare no potential conflicts of interest.